

Update on Impression Placement and Lodgement of Cleansing Prospectus

Following Impression Healthcare Limited's (**Impression**) announcement on 3 July 2019 of its successful capital raising of \$1.65 million, Impression is pleased to announce that it has received an additional \$50,000 in firm commitments as part of the placement, bringing the total amount raised to \$1.7 million.

The placement will be conducted across two tranches with a total of 44,736,844 shares and 22,368,422 attaching options (one (1) option for every two (2) shares) to be issued raising a total of \$1.7 million (before costs) (**Placement**). The additional \$50,000 in firm commitments has been received from non-executive Director, Peter Widdows and will form part of the second tranche of the Placement, to be issued subject to shareholder approval at an EGM expected to occur in August 2019. This increases Peter Widdows' shareholdings in Impression from 10,966,666 to 12,282,455 fully paid ordinary shares. A Change of Director's Interest Notice will be issued following the issue of the Placement.

As part of the Placement, Impression has today lodged a cleansing prospectus under section 708A(11) of the *Corporations Act 2001* (Cth) (**Corporations Act**) so that subsequent trading of Impression's shares and options issued under the first tranche of the Placement is not subject to secondary trading restrictions under the Corporations Act.

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is an innovative healthcare company that sells customised oral devices both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth-protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has broadened its commitment to disruption in the healthcare sector by progressing multiple opportunities in the field of medicinal cannabis. IHL has its licenses in place to import, export and distribute cannabis products. In March of 2019, Impression executed a binding collaboration with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. Cannvalate is Australia's largest distributor of medicinal cannabis products.

IHL also has a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated; a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand; and also intends to distribute medicinal cannabis oils through the Cannvalate network of cannabis medicine prescribers throughout Australia.

Investors: investors@impression.healthcare

Website: www.impression.healthcare